318 related articles for article (PubMed ID: 37085573)
21. [Eosinophilic granulomatosis with polyangiitis : Update on classification and management].
Hellmich B; Holle J; Moosig F
Z Rheumatol; 2022 May; 81(4):286-299. PubMed ID: 35075511
[TBL] [Abstract][Full Text] [Related]
22. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
23. Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review.
Mutoh T; Shirai T; Sato H; Fujii H; Ishii T; Harigae H
Rheumatol Int; 2022 Nov; 42(11):2069-2076. PubMed ID: 34287685
[TBL] [Abstract][Full Text] [Related]
24. Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis.
Matsuno O; Minamoto S
Respir Med Case Rep; 2022; 40():101763. PubMed ID: 36353062
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis.
Bloom JL; Langford CA; Wechsler ME
Rheum Dis Clin North Am; 2023 Aug; 49(3):563-584. PubMed ID: 37331733
[TBL] [Abstract][Full Text] [Related]
26. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Thiel J; Hässler F; Salzer U; Voll RE; Venhoff N
Arthritis Res Ther; 2013 Sep; 15(5):R133. PubMed ID: 24286362
[TBL] [Abstract][Full Text] [Related]
27. Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report.
Suzaki I; Tanaka A; Yanai R; Maruyama Y; Kamimura S; Hirano K; Kobayashi H
BMC Pulm Med; 2023 Apr; 23(1):130. PubMed ID: 37076824
[TBL] [Abstract][Full Text] [Related]
28. [Benralizumab in cases of eosinophilic granulomatosis with polyangiitis].
Carrette A; Mercier V; Lelubre C; Peché R
Rev Mal Respir; 2022 Sep; 39(7):621-625. PubMed ID: 35909008
[TBL] [Abstract][Full Text] [Related]
29. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
[TBL] [Abstract][Full Text] [Related]
30. Advances in the pharmacotherapeutic management of eosinophilic granulomatosis with polyangiitis.
Pagnoux C; Berti A
Expert Opin Pharmacother; 2023; 24(11):1269-1281. PubMed ID: 37204027
[TBL] [Abstract][Full Text] [Related]
31. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
[TBL] [Abstract][Full Text] [Related]
32. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
33. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV.
Sanchez-Alamo B; Schirmer JH; Hellmich B; Jayne D; Monti S; Tomasson G; Luqmani RA
RMD Open; 2023 Jun; 9(2):. PubMed ID: 37349121
[TBL] [Abstract][Full Text] [Related]
34. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
Yamane T; Hashiramoto A
Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
[TBL] [Abstract][Full Text] [Related]
35. Severe cardiomyopathy revealing antineutrophil cytoplasmic antibodies-negative eosinophilic granulomatosis with polyangiitis.
Bouiller K; Samson M; Eicher JC; Audia S; Berthier S; Leguy V; Humbert O; Martin L; Lorgis L; Cottin Y; Bonnotte B; Lorcerie B
Intern Med J; 2014 Sep; 44(9):928-31. PubMed ID: 25201426
[TBL] [Abstract][Full Text] [Related]
36. Successful benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.
Belfeki N; Abroug S; Ghriss N; Chouchane I; Hamrouni S; Strazzulla A; Zayet S
Clin Exp Rheumatol; 2021 Oct; 40(4):834-837. PubMed ID: 35522541
[TBL] [Abstract][Full Text] [Related]
37. Updates for the treatment of EGPA.
Raffray L; Guillevin L
Presse Med; 2020 Oct; 49(3):104036. PubMed ID: 32652104
[TBL] [Abstract][Full Text] [Related]
38. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
[TBL] [Abstract][Full Text] [Related]
39. [Steroids-Resistant EGPA-Induced Neuropathy with Acute Disease Progression: How to Use Mepolizumab as Novel Targeted Agent].
Hattori N
Brain Nerve; 2022 May; 74(5):531-536. PubMed ID: 35589643
[TBL] [Abstract][Full Text] [Related]
40. Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions.
Ushio Y; Wakiya R; Kato M; Kameda T; Nakashima S; Shimada H; Mansour MMF; Sugihara K; Miyashita T; Kadowaki N; Dobashi H
Mod Rheumatol Case Rep; 2021 Jul; 5(2):327-332. PubMed ID: 33533698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
